866-997-4948(US-Canada Toll Free)

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Published By :

GBI Research

Published Date : Sep 2013

Category :

Pharmaceutical

No. of Pages : N/A


GBI Research, the leading business intelligence provider, has released its latest research: Solid Tumors in Asia-Pacific Market to 2019 - New and Anticipated Approvals of Targeted Therapies to Trigger a Shift in Treatment Paradigm, which provides in-depth analysis of four key therapeutic indications within the Asia-Pacific (APAC) solid tumors market – bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer – covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these four solid tumor types. 

The value of the solid tumors market in the APAC region amounted to an estimated $1 billion in 2012 and is expected to register a modest Compound Annual Growth Rate (CAGR) of 12.3% to reach $2.3 billion in 2019. The key drivers for growth in this market include: new product approvals in ovarian, pancreatic and prostate cancers; expected launches from the promising ovarian and prostate cancer pipelines; and increased market penetration due to the anticipated implementation of social insurance in China. Conversely, the growth of the market in this region could face some restricting influences, including: the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; low access and penetration; and price erosion due to generic competition.
Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the bladder cancer, ovarian cancer, pancreatic cancer and prostate cancer in the four APAC markets of Australia, China, India and Japan.

The report includes:

  • Disease overview, as well as treatment algorithms and treatment usage patterns
  • Market size and forecast for the APAC solid tumors market from 2012 to 2019
  • Major marketed products in the APAC region for all four solid tumor types covered
  • In-depth pipeline analysis for all four solid tumor types
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements in the solid tumors market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the solid tumors market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Solid Tumors Market in Asia Pacific to 2019 - Introduction
2.1 Introduction

3 Solid Tumors Market in Asia Pacific to 2019 - Therapeutic Landscape
3.1 Bladder Cancer
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Diagnosis
3.1.5 Classification
3.1.6 Epidemiology
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Ovarian Cancer
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Diagnosis
3.2.5 Classification
3.2.6 Epidemiology
3.2.7 Prognosis and Disease Staging
3.2.8 Treatment Options
3.3 Pancreatic Cancer
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Classification
3.3.6 Epidemiology
3.3.7 Prognosis and Disease Staging
3.3.8 Treatment Algorithm
3.4 Prostate Cancer
3.4.1 Symptoms
3.4.2 Etiology
3.4.3 Pathophysiology
3.4.4 Co-Morbidities and Complications
3.4.5 Diagnosis
3.4.6 Classification
3.4.7 Epidemiology
3.4.8 Prognosis and Disease Staging
3.4.9 Treatment Options

4 Solid Tumors Market in Asia Pacific to 2019 - Marketed Products
4.1 Bladder Cancer
4.2 Ovarian Cancer
4.3 Pancreatic Cancer
4.4 Prostate Cancer
4.5 Key Marketed Products
4.5.1 Carboplatin
4.5.2 Cisplatin
4.5.3 Gemcitabine
4.5.4 Paclitaxel
4.5.5 Doxorubicin
4.5.6 Avastin (bevacizumab)
4.5.7 Tarceva (erlotinib)
4.5.8 Sutent (sunitinib)
4.5.9 Afinitor (everolimus)
4.5.10 Taxotere (docetaxel)
4.5.11 Zytiga (abiraterone acetate)
4.5.12 Jevtana (cabazitaxel)

5 Solid Tumors Market in Asia Pacific to 2019 - Pipeline Analysis
5.1 Bladder Cancer Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Ovarian Cancer Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Pancreatic Cancer Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Prostate Cancer Pipeline
5.4.1 Overall Pipeline
5.4.2 Pipeline Analysis by Molecule Type
5.4.3 Pipeline Analysis by Mechanism of Action
5.5 Promising Drug Candidates in the Pipeline
5.5.1 Abraxane (albumin-bound paclitaxel)
5.5.2 AMG 386 (trebananib)
5.5.3 Votrient (pazopanib)
5.5.4 Xtandi (enzalutamide)

6 Solid Tumors Market in Asia Pacific to 2019- Market Forecast
6.1 Asia-Pacific Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 India
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 Australia
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Japan
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Drivers and Barriers for the Solid Tumors Market in APAC
6.6.1 Drivers
6.6.2 Barriers

7 Solid Tumors Market in Asia Pacific to 2019 - Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-Development Deals
7.2.1 ScinoPharm Taiwan and Coland Enter into Agreement to Develop Generic Oncological Drugs
7.2.2 Bind Biosciences Enters into Agreement with Amgen to Develop Cancer Drugs
7.2.3 Merck Enters into Co-Development Agreement with Endocyte for Cancer Drug
7.2.4 Merck Serono Enters into Co-Development Agreement with Threshold Pharma for TH-302,
Pancreatic Cancer Drug
7.2.5 Seattle Genetics Exercises Option for Co-Development Agreement with Agensys (affiliate of
Astellas) for ASG-15ME
7.3 Major Licensing Deals
7.3.1 Spectrum Pharma Amends Licensing Agreement with Allergan for Apaziquone
7.3.2 Chugai Pharma Enters Into Licensing Agreement with Debiopharm Group for FF284
7.3.3 Baxter International Enters into Licensing Agreement with Onconova Therapeutics for
Rigosertib
7.3.4 Dyax Enters Into Licensing Agreement with Kadmon for Oncology Drug
7.3.5 Medigene Extends Licensing Agreement with Syncore for EndoTAG-1

8 Solid Tumors Market in Asia Pacific to 2019 - Appendix
8.1 Pipeline Drugs by Phase
8.1.1 Phase III
8.1.2 Pre-registration/NDA-filed
8.2 Market Forecasts to 2018
8.2.1 APAC
8.2.2 Australia
8.2.3 China
8.2.4 India
8.2.5 Japan
8.3 Market Definitions
8.4 Abbreviations
8.5 Sources
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Table


Table 1: Solid Tumors Market, Bladder Cancer, AJCC TNM Staging System, 2010
Table 2: Solid Tumors Market, Bladder Cancer, Treatment by Staging, 2013
Table 3: Solid Tumors Market, Ovarian Cancer, AJCC’s TNM and FIGO Staging Systems, 2013
Table 4: Solid Tumors Market, Pancreatic Cancer, AJCC TNM Staging System, 2013
Table 5: Solid Tumors Market, Prostate Cancer, AJCC Staging System, 2013
Table 6: Solid Tumors Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Solid Tumors Market, Global, Pharmaceutical Pipeline (Pre-registration/NDA-filed), 2013
Table 8: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Market Forecast, 2012–2019
Table 9: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Market Forecast, 2012–2019
Table 10: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Market Forecast, 2012–2019
Table 11: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Market Forecast, 2012–2019
Table 12: Solid Tumors Market, Australia, Ovarian Cancer, Market Forecast, 2012–2019
Table 13: Solid Tumors Market, Australia, Bladder Cancer, Market Forecast, 2012–2019
Table 14: Solid Tumors Market, Australia, Pancreatic Cancer, Market Forecast, 2012–2019
Table 15: Solid Tumors Market, Australia, Prostate Cancer, Market Forecast, 2012–2019
Table 16: Solid Tumors Market, China, Ovarian Cancer, Market Forecast, 2012–2019
Table 17: Solid Tumors Market, China, Bladder Cancer, Market Forecast, 2012–2019
Table 18: Solid Tumors Market, China, Pancreatic Cancer, Market Forecast, 2012–2019
Table 19: Solid Tumors Market, China, Prostate Cancer, Market Forecast, 2012–2019
Table 20: Solid Tumors Market, India, Ovarian Cancer, Market Forecast, 2012–2019
Table 21: Solid Tumors Market, India, Bladder Cancer, Market Forecast, 2012–2019
Table 22: Solid Tumors Market, India, Pancreatic Cancer, Market Forecast, 2012–2019
Table 23: Solid Tumors Market, India, Prostate Cancer, Market Forecast, 2012–2019
Table 24: Solid Tumors Market, Japan, Ovarian Cancer, Market Forecast, 2012–2019
Table 25: Solid Tumors Market, Japan, Bladder Cancer, Market Forecast, 2012–2019
Table 26: Solid Tumors Market, Japan, Pancreatic Cancer, Market Forecast, 2012–2019
Table 27: Solid Tumors Market, Japan, Prostate Cancer, Market Forecast, 2012–2019

List of Chart


Figure 1: Solid Tumors Market, Asia-Pacific, Bladder Cancer, Epidemiology, 2012–2019
Figure 2: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Superficial and Stage I, 2013
Figure 3: Solid Tumors Market, Bladder Cancer, Treatment Algorithm, Stage II and III, 2013
Figure 4: Solid Tumors Market, Asia-Pacific, Ovarian Cancer, Epidemiology, 2012–2019
Figure 5: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage I and II, 2013
Figure 6: Solid Tumors Market, Ovarian Cancer, Treatment Algorithm, Stage III and IV, 2013
Figure 7: Solid Tumors Market, Asia-Pacific, Pancreatic Cancer, Epidemiology, 2012–2019
Figure 8: Solid Tumors Market, Pancreatic Cancer, Treatment Algorithm, 2013
Figure 9: Solid Tumors Market, Asia-Pacific, Prostate Cancer, Epidemiology, 2012–2019
Figure 10: Solid Tumors Market, Prostate Cancer, Treatment Algorithm, 2013
Figure 11: Solid Tumors Market, Global, Avastin, Annual Sales ($m), 2006–2013e
Figure 12: Solid Tumors Market, Global, Tarceva, Annual Sales ($m), 2006–2013e
Figure 13: Solid Tumors Market, Global, Sutent, Annual Sales ($m), 2006–2013e
Figure 14: Solid Tumors Market, Global, Afinitor, Annual Sales ($m), 2009–2013e
Figure 15: Solid Tumors Market, Global, Zytiga, Annual Sales ($m), 2011–2013e
Figure 16: Solid Tumors Market, Global, Jevtana, Annual Sales ($m), 2010–2013e
Figure 17: Solid Tumors Market, Global, Bladder Cancer, Pipeline, 2013
Figure 18: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Molecule Type, 2013
Figure 19: Solid Tumors Market, Global, Bladder Cancer, Pipeline by Mechanism of Action, 2013
Figure 20: Solid Tumors Market, Global, Ovarian Cancer, Pipeline, 2013
Figure 21: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Molecule Type, 2013
Figure 22: Solid Tumors Market, Global, Ovarian Cancer, Pipeline by Mechanism of Action, 2013
Figure 23: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline, 2013
Figure 24: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Molecule Type, 2013
Figure 25: Solid Tumors Market, Global, Pancreatic Cancer, Pipeline by Mechanism of Action, 2013
Figure 26: Solid Tumors Market, Global, Prostate Cancer, Pipeline, 2013
Figure 27: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Molecule Type, 2013
Figure 28: Solid Tumors Market, Global, Prostate Cancer, Pipeline by Mechanism of Action, 2013
Figure 29: Solid Tumors Market, Asia-Pacific, Market Size ($m), 2012–2019
Figure 30: Solid Tumors Market, India, Market Size ($m), 2012–2019
Figure 31: Solid Tumors Market, Australia, Market Size ($m), 2012–2019
Figure 32: Solid Tumors Market, China, Market Size ($m), 2012–2019
Figure 33: Solid Tumors Market, Japan, Market Size ($m), 2012–2019
Figure 34: Solid Tumors Market, Global, Deals, 2006–2013
Figure 35: Solid Tumors Market, Global, Co-development Deals, 2006–2013
Figure 36: Solid Tumors Market, Global, Licensing Deals, 2006-2013
Figure 37: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Anti-Infective Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

    Anti-infective antibodies are being used extensively nowadays to treat serious bacterial and viral diseases such as pneumonia, tuberculosis and malaria. According to the World Health Organization, six major infectious diseases namely diarrhea, pneumonia, malaria, acquired immune deficiency syndrome (AIDS) , measles and tuberculosis are responsible for half of the premature deaths worldwide killing children and young adults. Moreover, threatenin...

  • DNA Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    The completion of human genome project resulted in discovery of several human disease causing genes. This discovery has further led to the evolution of DNA diagnostic platforms and resulted in the transformation of DNA diagnostics platforms from a research based activity into a major professional or commercial activity. The transformation is majorly attributed to the rapid pace of technological advances followed by development of robust methodo...

  • Alzheimers Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018

    Alzheimer’s disease is a neurological disorder of the brain which is progressive and ultimately leads to loss of neurons. This condition leads to loss of memory and reasoning abilities. Currently, there is no treatment for Alzheimer’s, although there are certain ways of slowing down its progression. Physicians generally prescribe neurotransmitters like cholinesterase inhibitors, memantine, etc. to slow down the advancement of diseas...